Source comparison
Melanotan-1 Contraindications: Research Contraindication Comparison
Melanoma or skin cancer history Absolute MC1R agonism may stimulate melanocyte proliferation in malignant or atypical cells via cAMP-CREB pathway Full-body dermatology exam at baseline + every 3 months Non-negotiable exclusion. Melanocortin receptor activation
This comparison does not assign a generated winner or score.
- Melanoma or skin cancer history
- Absolute
- MC1R agonism may stimulate melanocyte proliferation in malignant or atypical cells via cAMP-CREB pathway
- Full-body dermatology exam at baseline + every 3 months
- Non-negotiable exclusion. Melanocortin receptor activation directly intersects melanoma pathophysiology
- Severe renal impairment (eGFR <30)
- Impaired renal clearance causes drug accumulation, prolonged receptor occupancy, MC3R/MC4R cross-reactivity
- Serum creatinine + eGFR at baseline, monthly if risk factors present
- Dose reduction insufficient. Clearance reduced 60–75%, systemic effects unpredictable
- Pregnancy or lactation
- MC1R and MC4R expressed in placental tissue; melanocortin effects on fetal melanocyte migration undefined
- Serum beta-hCG within 7 days of first dose, monthly during dosing
- Requires 90-day washout post-dose due to prolonged melanogenesis duration
- Autoimmune disorders (vitiligo, lupus)
- Relative to Absolute
- MC1R modulates immune signaling; agonism may exacerbate autoantibody production or melanocyte destruction
- Baseline autoantibody panel if history present; clinical assessment every 4 weeks
- Vitiligo is near-absolute due to paradoxical melanocyte loss; SLE requires case-by-case evaluation
- Moderate renal impairment (eGFR 30–60)
- Relative
- Reduced clearance requires dose reduction to prevent accumulation
- eGFR every 4 weeks during active dosing
- 50% dose reduction + 72-hour inter-dose interval standard protocol adjustment
- Cardiovascular disease or uncontrolled hypertension
- MC3R and MC4R agonism can elevate blood pressure and heart rate through central sympathetic activation
- Blood pressure monitoring at every visit; baseline ECG if cardiac history
- SBP >160 mmHg or DBP >100 mmHg at baseline disqualifies until controlled